Susquehanna International Group’s Elicio Therapeutics ELTX Stock Holding History

Susquehanna International Group’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$757K	Buy	70,804 +6,752	+11%	+$65.2K	﹤0.01%	8615
2025 Q4	$510K	Sell	64,052 -56,155	-47%	-$510K	﹤0.01%	8741
2025 Q3	$1.32M	Buy	120,207 +103,184	+606%	+$1.04M	﹤0.01%	6681
2025 Q2	$131K	Sell	17,023 -14,338	-46%	-$89.2K	﹤0.01%	11603
2025 Q1	$193K	Buy	+31,361	New	+$243K	﹤0.01%	10967
2022 Q4	–	Sell	-1,366	Closed	-$13K	–	12713
2022 Q3	$13K	Sell	1,366 -568	-29%	-$5.93K	﹤0.01%	12731
2022 Q2	$22K	Buy	+1,934	New	+$30.9K	﹤0.01%	12339

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ELTX Position: Q1 2026 in Review

Susquehanna International Group increased its Elicio Therapeutics (ELTX) stake by 11% in Q1 2026, buying an estimated $65.2K and bringing the position to 70,804 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #8615.

Susquehanna International Group first reported a position in ELTX in Q2 2022 and has held it in 7 quarters since. The position peaked at $1.32M in Q3 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Susquehanna International Group held 70,804 shares of Elicio Therapeutics worth $757K as of Q1 2026.
Susquehanna International Group bought 6,752 Elicio Therapeutics shares in Q1 2026, an estimated $65.2K.
Elicio Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8615 holding.
Susquehanna International Group first reported a position in Elicio Therapeutics in Q2 2022 and has held it in 7 quarters since.
Susquehanna International Group's Elicio Therapeutics position peaked at $1.32M in Q3 2025.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.